



**HAL**  
open science

## **Antibodies attenuate the capacity of dendritic cells to stimulate HIV-specific cytotoxic T lymphocytes**

Wilfried Posch, Sylvain Cardinaud, Chiraz Hamimi, Adam Fletcher, Annelies Mühlbacher, Klaus Loacker, Paul Eichberger, Manfred P. Dierich, Gianfranco Pancino, Cornelia Lass-Flörl, et al.

### ► To cite this version:

Wilfried Posch, Sylvain Cardinaud, Chiraz Hamimi, Adam Fletcher, Annelies Mühlbacher, et al.. Antibodies attenuate the capacity of dendritic cells to stimulate HIV-specific cytotoxic T lymphocytes. *Journal of Allergy and Clinical Immunology*, 2012, 130 (6), pp.1368–1374.e2. 10.1016/j.jaci.2012.08.025 . pasteur-01420581

**HAL Id: pasteur-01420581**

**<https://pasteur.hal.science/pasteur-01420581v1>**

Submitted on 16 May 2017

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial - ShareAlike 4.0 International License

## **Antibodies attenuate the capacity of dendritic cells to stimulate HIV-specific CTLs**

Wilfried Posch, PhD<sup>1</sup>, Sylvain Cardinaud, PhD<sup>2</sup>, Chiraz Hamimi, MSc<sup>3</sup>, Adam Fletcher, PhD<sup>4</sup>, Annelies Mühlbacher, MD<sup>5</sup>, Klaus Loacker, PhD<sup>5</sup>, Paul Eichberger, PhD<sup>6</sup>, Manfred P. Dierich, MD<sup>1</sup>, Gianfranco Pancino, MD, PhD<sup>3</sup>, Cornelia Lass-Flörl, MD<sup>1</sup>, Arnaud Moris, PhD<sup>2</sup>, Asier Saez-Cirion, PhD<sup>3</sup>, and Doris Wilflingseder, PhD<sup>1\*</sup>

<sup>1</sup> Division of Hygiene and Medical Microbiology, Innsbruck Medical University, Fritz-Preglstr. 3, Innsbruck, Austria

<sup>2</sup> INSERM UMRS-945, Infection and Immunity, Hôpital La Pitié-Salpêtrière, Université Pierre et Marie Curie (Paris-6), 91 Bd de l'Hôpital, Paris, France

<sup>3</sup> Unité de Régulation des Infections Rétrovirales, Institut Pasteur, 25 Rue du Docteur Roux, 75724 Paris, France

<sup>4</sup> MRC/UCL Centre for Medical Molecular Virology, Division of Infection and Immunity, University College London, 46 Cleveland Street, London, W1T 4JF, UK

<sup>5</sup> Central Institute for Blood Transfusion & Immunological Department, Anichstrasse 35, Innsbruck, Austria

<sup>6</sup> Department of Therapeutic Radiology and Oncology, Anichstrasse 35, Innsbruck, Austria

**Running title:** IgG opsonization impedes HIV-CTL priming

\*Corresponding Author:

Doris Wilflingseder

Division of Hygiene and Medical Microbiology

Innsbruck Medical University

Fritz-Pregl-Str. 3.

A-6020 Innsbruck

Austria

Tel.: 0043-512-900370784

Fax: 0043512-900373700

E-mail: [doris.wilflingseder@i-med.ac.at](mailto:doris.wilflingseder@i-med.ac.at)

## **Abstract**

**Background:** Control of HIV is suggested to depend on potent effector functions of the virus-specific CD8<sup>+</sup> T cell response. Antigen opsonization can modulate the capture of antigen, its presentation and the priming of specific CD8<sup>+</sup> T cell responses.

**Objective:** We have previously shown, that opsonization of retroviruses acts as endogenous adjuvant for DC-mediated induction of specific CTLs. However, in some HIV-positive individuals, high levels of antibodies and low levels of complement fragments coat the HIV surface.

**Methods:** Therefore, we analyzed the impact of IgG-opsonization on the antigen-presenting capacity of DC by CD8<sup>+</sup> T cell proliferation assays following repeated prime-boosting, by measuring the antiviral activity against HIV-infected autologous CD4<sup>+</sup> T cells, and by IFN- $\gamma$  secretion from HIV-specific CTL clones.

**Results:** We find that DC exposed to IgG-opsonized HIV significantly decreased the HIV-specific CD8<sup>+</sup> T cell response compared to the earlier described efficient CD8<sup>+</sup> T cell activation induced by DC loaded with complement-opsonized HIV. DC exposed to HIV bearing high surface IgG levels, following incubation in plasma from HIV-infected individuals, acted as weak stimulators for HIV-specific CTL clones. In contrast, HIV opsonized with plasma from patients exhibiting high C and low IgG deposition on the viral surface favored significantly higher activation of HIV-specific CD8<sup>+</sup> T cell clones.

**Conclusion:** Our *ex vivo* and *in vitro* observations provide the first evidence that IgG-opsonization of HIV is associated with a decreased CTL-stimulatory capacity of DC.

## **Key Messages**

- Plasma from HIV positive individuals with high complement activity mediates high CTL-induction.
- First *ex vivo* and *in vitro* evidence for decreased CTL-stimulatory capacity of DC exposed to Ab HIV.
- Implication that strong Ab response after vaccination contribute to weaken CTL by DC modulation.

## **Capsule Summary**

Our results are relevant regarding HIV vaccination strategies as they suggest that strong, transient Ab responses after vaccination might contribute to weaken CTL-induction by modulation of DC function as observed in our study.

**Keywords:** HIV, IgG, opsonization, DC, CTLs

### **Abbreviations:**

HIV - human immunodeficiency virus

DC – dendritic cell, iDC – immature dendritic cell, mDC – mature dendritic cell

CTL – cytotoxic T lymphocyte

IgG – immunoglobulin G

(n)Ab – (neutralizing) antibodies

C – complement

SEB – staphylococcal enterotoxin B

## **Introduction**

Appearance of HIV-specific CTLs correlates with declining viremia during the acute phase of infection. During the chronic phase of infection, HIV-CTL are exhausted and are not able to efficiently control infection [1-5]. However, some individuals who commonly have viral loads below standard detection levels without undergoing antiretroviral therapy (HIV controllers), possess efficient CD8<sup>+</sup> T cells able to proliferate, produce multiple cytokines and upregulate cytolytic molecules in response to antigen stimulation and endowed with a strong capacity to eliminate infected CD4<sup>+</sup> T cells [6-10].

HIV-1 initiates immediate responses of the immune system upon crossing mucosal surfaces. There, the complement (C) system constitutes a first line of defense against the virus. Recently, we illustrated an important role for C-opsonization of retroviruses as an endogenous adjuvant for DC-mediated CTL-induction [11]. The first antibody responses to HIV-1 envelope glycoproteins gp41 and gp120 appear in plasma two weeks and four weeks post infection, respectively. These antibodies were demonstrated to have only modest impact on viral load [12-14]. Nevertheless, HIV is opsonized by antibodies and complement fragments after appearance of the first antibodies. After months of infection, neutralizing antibodies (nAbs) appear, becoming increasingly potent in some individuals to develop broadly neutralizing capacity [15, 16]. Whether HIV-1 nAbs confer viral control in HIV long term non-progressors (LTNP) or elite HIV controllers is not clear [17-19]. Independent of neutralizing capacity, binding of specific antibodies to the HIV surface increases and results in either amplification of C activation and deposition on the HIV surface (HIV-C), or enhanced interaction of HIV-bound antibodies (HIV-Ig) with Fc receptors expressed on hematopoietic cells. Immune complexes containing infectious viral particles have been identified in blood and on lymphoid follicles of HIV-positive individuals [20, 21]. Previously, we have shown that a differential opsonization pattern results in differential outcomes in DC infection, viral

integration and long-term transmission to T cells [22, 23]. Moreover, upon retroviral infections, complement opsonization seems to favor effective CTL priming by DC [11]. Thus, the opsonization pattern of HIV-1 does not merely result in differential DC infection and integration, but it also has profound consequences on the antigen-presenting capacity of DC *in vitro* and *in vivo*.

Here we sought to understand whether DC exposed to IgG-opsonized HIV are comparable in CTL-stimulatory capacity to HIV-C-DC. Using *in vitro* priming experiments, we find that DC exposed to IgG-opsonized HIV significantly decreased the HIV-specific CD8<sup>+</sup> T cell response compared to the efficient HIV-C-DC-induced CD8<sup>+</sup> T cell activation described earlier [11]. DC exposed to HIV bearing high surface IgG levels, following incubation in plasma from HIV-infected individuals, acted as weak stimulators for HIV-specific CTL clones. In contrast, HIV opsonized with plasma from patients exhibiting high C and low IgG deposition on the viral surface favored significantly higher activation of HIV-specific CD8<sup>+</sup> T cell clones. Our *ex vivo* and *in vitro* observations provide the first evidence that IgG-opsonization of HIV is associated with a decreased CTL-stimulatory capacity of DC.

## **Methods**

### *Samples*

Plasma samples were obtained from 35 HIV infected individuals recruited among patients followed-up in CHU St Louis, Hopital European Georges Pompidou and CHU de Bicetre in France. All the subjects gave their informed consent to participate in the study. The Ethics review committee CPP (Comité de protection des personnes) Ile de France VII and the Clinic Research Committee of Institut Pasteur approved the studies performed.

A written informed consent was also obtained from the participating blood donors by the Central Institute for Blood Transfusion & Immunological Department, Innsbruck, Austria, to isolate monocytes and naive CD4<sup>+</sup> and CD8<sup>+</sup> T cells from the blood packs.

### *Generation of primary human monocyte-derived DCs and isolation of human CD4<sup>+</sup> and CD8<sup>+</sup> T cells*

Monocytes were isolated from blood of normal healthy donors by using human CD14 MicroBeads (Miltenyi Biotec), according to the manufacturer's instructions. DCs were generated and analyzed as described [11, 23]. Subsequently, CD4<sup>+</sup> (>95% purity) and CD8<sup>+</sup> (>94% purity) T cells were bead-purified and used with autologous DC's for the *in vitro* experiments.

### *Opsonization of HIV-1*

Purified R5-tropic HIV (BaL, 92UG037) was incubated for 1 hr at 37°C with normal human serum (NHS) as complement (C) source (HIV-C) or commercially available human C serum (Quidel) (HIV-C (human C serum, Quidel)) in a 1:10 dilution, with IgGs (50 µg/ml; Centre

for AIDS Reagents) to obtain IgG-opsonized virus (HIV-Ig), or a combination of both (HIV-CIg). As negative control the virus was incubated under the same conditions in medium or heat-inactivated serum (HIV). For experiments using plasma samples from HIV infected individuals, HIV (BaL and 92UG037, concentration >1 µg/ml) was incubated under above mentioned conditions using the plasma in a 1:10 dilution. Subsequent to opsonization, the virus was washed, pelleted by ultracentrifugation (14000 rpm/90 min/4°C) and re-suspended in 100 µl RPMI medium without supplements. The opsonization pattern was determined by virus capture assay (VCA) as described [23] using anti-human C3c/C3d-, IgG- or mouse IgG Abs as control for background binding. The coated VCA plates were incubated overnight with the differentially opsonized virus preparations (2.5 ng p24/well) at 4°C and washed 5 times using RPMI medium to remove unbound virus. Bound virus was lysed (2% Igepal) and transferred to a pre-coated p24 ELISA plate [24].

### *Prime-boost experiments*

The *in vitro* generated CD8<sup>+</sup> T cells were analyzed for expansion by FACS analyses, and functionality (antiviral assay) as described [11], but detailed description of the *in vitro* CD8<sup>+</sup> T cell generation and antiviral activity testing is additionally provided below.

### *In vitro generation of HIV-specific CD8<sup>+</sup> T cells*

Day 5 iDC were stimulated with a cytokine-cocktail (IL-1β, IL-6, PGE<sub>2</sub>, TNF-α, IL-4, GM-CSF) for 24 hrs and then 10<sup>4</sup> cells/100 µl were transferred into 96-well plates. DC from all donors were loaded with 25 ng p24/ml non- (HIV), complement- (HIV-C), complement plus antibody- (HIV-CIg) or antibody-opsonized (HIV-Ig) HIV strains (R5-, R5X4- and X4-tropic) for 3 hrs. DC were exposed to 1 µg/ml of the superantigen Staphylococcal Enterotoxin B



(SEB, Sigma) for the same time-period as a positive control for T cell proliferation. As additional controls iDC and/or cytokine cocktail-stimulated DCs (ccDC) were included in the experimental settings. All tests were performed in triplicates. The cells were thoroughly washed and non-stimulated, naïve CD8<sup>+</sup> T cells were added to the primed DC at a ratio 3:1. 25 U/ml IL-2 was added after 4 days and after another 4 days the T cells were again boosted with loaded DCs. This procedure was repeated 3 times and the CD8<sup>+</sup> cells were analyzed for expansion, IFN- $\gamma$  secretion, and functionality. HIV-induced proliferation of T cells was analyzed by FACS. Proliferated T cells were expanded with the CD3/CD28 T cell expander (Dyna) according to the manufacturer after the third priming with loaded DCs to perform tests for the antiviral activity of the *in vitro* generated HIV-specific CTLs.

#### *Anti-HIV-activity of in vitro generated cytotoxic T cells*

To further determine the functionality of the *in vitro* generated HIV-specific CTLs, frozen autologous CD4<sup>+</sup> T cells were thawed, washed, and stimulated with CD3/CD28 beads (Dyna) in presence of IL-2 (100 U/ml). Pre-stimulation of the CD4<sup>+</sup> T cells with CD3/CD28 was necessary to induce the up-regulation of CCR5. The *in vitro* primed and expanded CTLs were added to over night HIV-incubated CD4<sup>+</sup> T cells. A reduction in virus production assessed by p24 ELISA on several days post addition of the expanded CTLs indicated an indirect confirmation of their functionality. By using this assay we were in addition able to circumvent the problem of the unknown HLA-type of the majority of the donors. This indirect confirmation of the functionality was performed with expanded CTLs from seven donors primed and boosted with HIV-exposed DCs. Both methods (*in vitro* generation and antiviral assay) were performed exactly as described in Banki et al., 2010 [11].

### *HIV-specific CTLs and Elispot analyses*

SL9 clone 2, an HIV-specific CD8<sup>+</sup> CTL clone, was derived from an HIV-infected patient and recognizes the well-characterized immunodominant epitope of Gag p17 SLYNTVATL (SL9) presented by HLA-A\*020 [25, 26]. Loaded DC were co-cultured overnight with CD8<sup>+</sup> T cell clones (ranging from 2500 to 10000 SL9 clone 2/well). As positive controls, stimulators (i.e. DC) were incubated with 1 µg/ml of cognate peptide (SLYNTVATL, SL9) before washing and addition of the HIV-specific CTL clones overnight. The next day, IFN- $\gamma$  production was monitored in an Elispot assay as described [25]. All Abs used for the IFN- $\gamma$  Elispot were from Mabtech.

### *Immunofluorescence and confocal microscopy*

For intracellular HIV localization iDC were exposed to differentially opsonized HIV (250 ng of p24/2.5 × 10<sup>5</sup> cells) overnight. After washing, cells were left to adhere on glass coverslips for 1 h at 37°C. Cells were then fixed and permeabilized 20 min at 4°C in BD Cytotfix/Cytoperm (BD Biosciences) and washed with BD Perm/Wash™ buffer containing human IgG (20 µg/condition). Triple labeling of cells was done as follows: iDC pulsed with HIV-1 were stained with primary Abs against HLA-ABC (BD Biosciences), CD63 (monoclonal (1B5)), and LAMP-1 (polyclonal Ab). After extensive washing, cells were then stained with secondary donkey anti-mouse and anti-rabbit Abs coupled to rhodamine (Jackson ImmunoResearch Laboratories). To avoid unspecific labeling, cells were incubated 20 min at room temperature in PBS containing BSA, saponin, and mouse serum (0.5 mg/ml). Finally, HIV-1-p24<sup>gag</sup> was detected using a monoclonal anti-HIV-1-p24<sup>gag</sup> (KC57) coupled to FITC (Beckman-Coulter). Confocal laser scanning microscopy was performed with an LSM 510 microscope (Zeiss). Images were then processed using Photoshop. Quantifications of

colocalization were performed using the Metamorph software (Universal Imaging) on an average of 25–30 cells for each condition as previously described [27].

### *Statistical analysis*

Differences were analyzed by the GraphPad prism software using the unpaired student's t-test (2-tailed) for comparisons between two groups. For multiparameter comparisons, values from the experiments were logarithmically transformed and analysed using ANOVA and Bonferroni's multiple comparison test for selected groups.

## Results

### *IgG-opsonization of HIV interferes with DC-mediated CD8<sup>+</sup> T cell proliferation.*

To characterize the IgG-mediated effect on the CD8<sup>+</sup>-stimulatory capacity of HIV-loaded DC, we differentially opsonized live virus using a commercially available IgG pool (HIV-Ig [Centre for AIDS reagents]) and commercially available serum (HIV-C [human C serum, Quidel]) and applied the preparations in prime-boost experiments with cells from healthy donors. In accordance to our previous results [11], DC exposed to HIV-C triggered significantly more CD8<sup>+</sup> T cell proliferation than those loaded with non-opsonized HIV ( $p=0.0058$ , Fig. 1A). In contrast, DC loaded with IgG-opsonized HIV stimulated CD8<sup>+</sup> T cell expansion much less than HIV-C loaded DC ( $p=0.0111$ , Fig. 1). The CD8<sup>+</sup> T cell-stimulatory capacity of DC loaded with HIV opsonized in the presence of C and IgGs (HIV-CIg) was intermediate and not significantly different from HIV-C or HIV-Ig (Fig. 1). Staphylococcus enterotoxin B (SEB)-stimulated CD8<sup>+</sup> T cell proliferation served as positive control, and expansion by cytokine-loaded DC and iDC as negative controls (Fig. 1, SEB, mDC, iDC). Figure 1A illustrates the average expansion of CD8<sup>+</sup> T cells from 5 donors and two different virus strains (BaL, 92UG037) compared to the positive control (SEB-DC-activated CD8<sup>+</sup> T cells). Thus, results for each sample (SEB, mDC, iDC, HIV, HIV-C, HIV-CIg, HIV-Ig) were confirmed 10 times. To further confirm the T cell expansion, CD8<sup>+</sup> T cells from 3 donors were labeled with CFSE prior the first priming with loaded DCs. Expanded CD8<sup>+</sup> T cells were measured as CFSE<sup>low</sup> population after the third boost and confirmed the data above (Suppl. Fig. 1).

### *HIV-Ig-DC-primed CD8<sup>+</sup> T cells elicit weaker anti-HIV activity than HIV-C-DC-primed CD8<sup>+</sup> T cells.*

It has been suggested that the efficiency of HIV-specific CD8<sup>+</sup> T cells is well illustrated by the capacity of these cells to suppress HIV-1 infection in co-cultures with infected CD4<sup>+</sup> T cells [8]. To place the above finding in the context of CD8<sup>+</sup> T cell-mediated control of virally infected CD4<sup>+</sup> T cells, we designed a co-culture experiment using our HIV-C- or HIV-Ig-loaded DC cells. HIV-Ig-DC-primed CD8<sup>+</sup> T cells elicited a weak but non-significant decrease in p24 production of infected, autologous CD4<sup>+</sup> T cells compared to SEB-DC-primed CD8<sup>+</sup> T cells (Fig. 2). In contrast, HIV-C-DC-primed CD8<sup>+</sup> T cells exerted a strong anti-HIV-activity against HIV-infected CD4<sup>+</sup> T cells (Fig. 2). Additionally, HIV-CIg-DC-CD8<sup>+</sup> T cells partially blocked infection in these co-cultures compared to HIV-Ig-DC-CD8<sup>+</sup> T cells ( $p = 0.0139$ , Fig. 2), but significantly weaker than HIV-C-DC-CD8<sup>+</sup> T cells ( $p = 0.0024$ , Fig. 2). These results suggest that the presence of Ig on the surface of viral particles counterbalances the positive effect of complement opsonization on the CTL-stimulatory capacity of DC. The assays were confirmed with cells isolated from 7 different donors using R5-, X4- and R5X4-tropic viral isolates or SEB for DC exposure. Thereby, the results were proved more than 20 times in triplicates for the various groups.

*HIV-specific CTL clones are activated to a significantly lower degree by DC exposed to HIV, which was coated with a high IgG/C ratio.*

We then evaluated the effect of HIV-opsonization using plasma from HIV-infected patients with different ratios of Ig and C on the ability of DC to induce CTL responses. We first screened the degree of complement activation or antibody binding to HIV-BaL *ex vivo* using plasma from 35 HIV-positive individuals and 10 healthy individuals. The IgG and C3-deposition on the viral surface was analyzed by a virus capture assay (VCA) as described [11]. As expected, HIV-BaL was covered with significantly more IgG ( $p < 0.0001$ ) and C3 fragments ( $p = 0.0016$ ) using plasma from 35 HIV-positive individuals compared to 10 healthy

controls (Fig. 3). Background IgG levels were measured on the surface of HIV-BaL, which was opsonized using plasma from healthy donors (Fig. 3, IgG VCA, red quadrants), HIV-C (human C serum, Quidel) (n=2) (Fig. 3, IgG VCA, green triangle) or the non-opsonized control (n=2) (Fig. 3, IgG VCA, blue triangle), thus excluding the presence of natural Abs on the surface of plasma or NHS-incubated virus preparations. Complement activation was also significantly higher in HIV-positive (n=35) compared to healthy (n=10) individuals (p=0.0016) (Fig. 3, C3 VCA, yellow circles, red quadrants). Non-opsonized control and HIV-C (human C serum, Quidel) preparations were added to each analysis as controls for functionality of the VCA. The VCA was performed using all plasma samples (35 HIV<sup>+</sup>, 10 healthy) and 2 different virus preparations (BaL, 92UG037).

We selected HIV preparations opsonized with plasma from HIV-infected individuals, which displayed a significantly higher IgG (Fig. 4, blue bars) to C (Fig. 4, red bars) ratio (Fig. 4, p = 0.0046) or vice versa (Fig. 4, p = 0.0025) to investigate the differential functional impact of complement- or IgG-opsonization on the antigen-presenting capacity of DC to HIV-specific CD8<sup>+</sup> T cell clones. Fig. 4 shows a representative VCA for HIV-C high or HIV-Ig high samples. Differences between HIV-C and HIV-Ig binding to the virus capture plate might be explained by diverse avidity of the Abs used in the VCA (mAb against human C3c or IgG). Nevertheless, the binding of the differentially opsonized HIV preparations is due to specific interactions with the various receptors expressed on DC as shown by experiments using blocking DC-SIGN, CR3 or CD32 Abs (not shown). Additionally, the amounts of IgGs or C3c bound on the surface of HIV after opsonization with the *ex vivo* plasma samples did not differ significantly (Suppl. Fig. 2).

DC were exposed to the HIV-C high or HIV-Ig high preparations, washed, and HLA-matched HIV-specific CD8<sup>+</sup> T cell clones were added at a 10:1 E:T ratio. The activation of the specific clones was measured by IFN $\gamma$  Elispot. We found that significantly less IFN- $\gamma$  spots were

induced when using HIV-Ig high-DC for stimulation compared to DC exposed to HIV-C high ( $p \leq 0.0001$ , Fig. 5) or HIV-C (human C serum, Quidel) ( $p \leq 0.001$ , Fig. 5). As positive controls for IFN $\gamma$  induction from HIV-specific CD8<sup>+</sup> T cells, peptide (SLYNTVATL)-loaded DC (pepDC) and DC exposed to human complement serum (HIV-C (human C serum, Quidel)), as negative controls immature DC (iDC), DC exposed to non-opsonized HIV (HIV) and DC loaded with IgG-opsonized HIV (MRC IgG-pool) were used. The results were verified with 10 preparations for each group (pepDC, iDC, HIV, HIV-C, HIV-Ig, HIV-C high, HIV-Ig high) in triplicates.

*In contrast to IgG-opsonized HIV, complement-coated virus co-localizes with HLA-ABC in DCs.*

To explain the different CTL-stimulatory capacity of C- and IgG-loaded DC, we performed confocal microscopic analyses using differentially loaded DC (HIV-C, HIV-CIg, HIV-Ig) and stained the cells with antibodies against various endo- and lysosomal markers or HLA-ABC and HIV-Gag (KC57-FITC). While after incubation with HIV-C, where HIV Gag co-localized with HLA-ABC in more than 90% of the investigated DCs (Fig. 6A, left panel and Fig. 6B), a significantly lower co-localization (31.5%) was observed after overnight incubation with HIV-Ig in DCs (Fig. 6A, right panel and Fig. 6B). The co-localization of HIV and HLA-ABC in HIV-CIg-incubated DCs was intermediate (Fig. 6A, middle panel and Fig. 6B). A significantly lower co-localization of HLA-ABC and HIV-p24 was observed in HIV-Ig-incubated DCs compared to HIV-C- and HIV-CIg-exposed cells ( $p \leq 0.0001$ ).

No increased co-localization of all different virus preparations (HIV, HIV-C, HIV-CIg (not shown), HIV-Ig) with late endosomes/multivesicular bodies (marker: CD63) or lysosomal compartments (marker: Lamp-1) was detected (Fig. 7). All confocal microscopic analyses

were performed using differentially opsonized 92UG037, 93BR020, and NL4-3. Quantifications of colocalization were performed using the Metamorph software (Universal Imaging) on an average of 20–25 cells for each condition as previously described [27].



## Discussion

The *ex vivo* and *in vitro* data presented in this study using plasma from HIV-infected individuals confirm our findings that complement acted as an endogenous adjuvant for DC-mediated induction of retroviral CTLs *in vitro* and *in vivo* [11], while we could show here that Ab coating of the viral surface significantly decreased the DC-mediated CTL activation. Investigations of DC interactions with differentially opsonized HIV are important, since *in vivo* HIV is found opsonized with complement fragments and specific IgGs in all compartments tested so far, i.e. plasma, seminal fluid [28], or HIV stripped from tonsillar tissue [29]. It has been shown that targeting Ag to Fc $\gamma$ R on DC increased Ab responses to soluble Ags and to tumor cells [30]. *In vitro* studies involving Fc $\gamma$ R uptake through the endosomal system demonstrated that, besides enhancing MHC class II antigenic processing [30-32] and presentation, this uptake provided access to the cytosolic or endogenous pathway [33-35]. A different co-localization of HIV-C or HIV-Ig with HLA class I molecules or the degradation of HIV-Ig in lysosomal compartments may constitute mechanisms explaining the weaker CD8<sup>+</sup> T cell stimulation of DC exposed to HIV-Ig. We now detected that when tracking HIV-C or HIV-Ig preparations and HLA-ABC intracellularly, the magnitude of Gag co-localization of HIV-C with HLA-class I was significantly higher compared to HIV-Ig-incubated cells. Co-localization of both, HIV-C and HIV-Ig, with other cellular markers such as CD63 (marker of late endosomes/multi vesicular bodies), HLA-DM, or Lamp-1 (marker of lysosomes) was marginal, while the tetraspanin-rich CD81-containing compartment was targeted by HIV-C and HIV-Ig in DCs as previously shown [23].

Efficient early CD8<sup>+</sup> T cell responses are critical in controlling HIV-1 replication and their determinant role in HIV-1 control is further supported by association of certain HLA class I alleles and an improved disease progression [36-38]. In view of our observations, we are proposing that during acute viral infection CD8<sup>+</sup> T cells are efficiently induced by DC,

probably due to (i) enhanced infection of DC by HIV-C [23] and presentation of endogenously synthesized viral Ags processed through HLA-ABC and (ii) more efficient cross-presentation from incoming complement-opsonized virus.

The novel modulatory effects of the HIV-opsonization state on the CTL-activating capacity of DC described herein call for further investigation, since current HIV vaccination strategies aim in developing a vaccine that efficiently induces both, a cellular as well as humoral immune response [39-41]. Thus far, disappointing results have been achieved in clinical trials targeting either cellular immunity [42, 43] or humoral immunity [44, 45]. The RV144 AIDS vaccine trial in Thailand [46] evoked strong, but transient Env-specific CD4<sup>+</sup> T cell and Ab responses, but only weak HIV-specific CD8<sup>+</sup> T cell responses [40, 47]. Our results are highly relevant in this regard as they suggest that strong, transient Ab responses after vaccination might contribute to weaken CTL-induction by modulation of DC function as uncovered in this *ex vivo* and *in vitro* study and thereby might play a critical role for future vaccination strategies.

## **Acknowledgements**

This work was supported by the Austrian Science Fund [FWF, P22165 and P24598 to DW] and the Tyrolean Science Fund [TWF, project: D-155140-016-011 to WP]. The authors thank Prof. Olivier Lambotte, Prof. Laurence Weiss, Dr. Caroline Lascoux, Dr. Olivier Taulera, Katia Bourdic, Jeannine Delgado, Maria Manea and all the other physicians and nurses who cared for the patients whose samples were included in the study. Additionally, we want to thank Polymun Scientific, Donaustrasse 99, Klosterneuburg, Austria who provided all reagents for p24 ELISA. The reagents ARP118 (HIV-BaL), ARP513 (HIVIg pool) and ARP177.8 (HIV-92UG037) were obtained from the Centre for AIDS Reagents, NIBSC HPA UK, supported by the EC FP6/7 Europrise Network of Excellence, and NGIN consortia and the Bill and Melinda Gates GHRC-CAVD Project and were donated by Dr.S.Gartner, Dr.M.Popovic, Dr.R.Gallo (Courtesy of the NIH AIDS Research and Reference Reagent Program [BaL]), Dr B. Wahren, The Swedish Institute for Infectious Disease Control, Stockholm, Sweden [HIVIg pool] and the WHO UN AIDS Network for HIV-isolation and characterization [92UG037].

**Conflict of Interest Statement:** The authors declare not to have any conflict of interest.

## References

1. Koup RA, Safrit JT, Cao Y, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. *J Virol* **1994**; 68:4650-5.
2. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MB. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. *J Virol* **1994**; 68:6103-10.
3. McMichael AJ, Rowland-Jones SL. Cellular immune responses to HIV. *Nature* **2001**; 410:980-7.
4. Freeman GJ, Wherry EJ, Ahmed R, Sharpe AH. Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. *J Exp Med*. **2006**; 203(10):2223-7.
5. Lewis MJ, Dagarag M, Khan B, Ali A, Yang OO. Partial Escape of HIV-1 From Cytotoxic T Lymphocytes During Chronic Infection. *J Virol* **2012**.
6. Saez-Cirion A, Pancino G, Sinet M, Venet A, Lambotte O. HIV controllers: how do they tame the virus? *Trends Immunol* **2007**; 28:532-40.
7. Lambotte O, Boufassa F, Madec Y, et al. HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. *Clin Infect Dis* **2005**; 41:1053-6.
8. Saez-Cirion A, Lacabaratz C, Lambotte O, et al. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. *Proc Natl Acad Sci U S A* **2007**; 104:6776-81.
9. Migueles SA, Osborne CM, Royce C, et al. Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. *Immunity* **2008**; 29:1009-21.
10. Miura T, Brumme ZL, Brockman MA, et al. Impaired replication capacity of acute/early viruses in persons who become HIV controllers. *J Virol* **2010**; 84:7581-91.
11. Banki Z, Posch W, Ejaz A, et al. Complement as an endogenous adjuvant for dendritic cell-mediated induction of retrovirus-specific CTLs. *PLoS Pathog* **2010**; 6:e1000891.
12. Tomaras GD, Yates NL, Liu P, et al. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. *J Virol* **2008**; 82:12449-63.
13. Haynes BF, Moody MA, Liao HX, Verkoczy L, Tomaras GD. B cell responses to HIV-1 infection and vaccination: pathways to preventing infection. *Trends Mol Med* **2011**; 17:108-16.
14. Bar KJ, Li H, Chamberland A, et al. Wide variation in the multiplicity of HIV-1 infection among injection drug users. *J Virol* **2010**; 84:6241-7.
15. Moog C, Fleury HJ, Pellegrin I, Kim A, Aubertin AM. Autologous and heterologous neutralizing antibody responses following initial seroconversion in human immunodeficiency virus type 1-infected individuals. *J Virol* **1997**; 71:3734-41.
16. Gray ES, Moody MA, Wibmer CK, et al. Isolation of a monoclonal antibody that targets the alpha-2 helix of gp120 and represents the initial autologous neutralizing-antibody response in an HIV-1 subtype C-infected individual. *J Virol* **2011**; 85:7719-29.

17. Cao Y, Qin L, Zhang L, Safrit J, Ho DD. Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. *N Engl J Med* **1995**; 332:201-8.
18. Montefiori DC, Pantaleo G, Fink LM, et al. Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. *J Infect Dis* **1996**; 173:60-7.
19. Lambotte O, Ferrari G, Moog C, et al. Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. *AIDS* **2009**; 23:897-906.
20. Heath SL, Tew JG, Szakal AK, Burton GF. Follicular dendritic cells and human immunodeficiency virus infectivity. *Nature* **1995**; 377:740-4.
21. Jakubik JJ, Saifuddin M, Takefman DM, Spear GT. Immune complexes containing human immunodeficiency virus type 1 primary isolates bind to lymphoid tissue B lymphocytes and are infectious for T lymphocytes. *J Virol* **2000**; 74:552-5.
22. Holl V, Peressin M, Decoville T, et al. Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells. *J Virol* **2006**; 80:6177-81.
23. Wilflingseder D, Banki Z, Garcia E, et al. IgG opsonization of HIV impedes provirus formation in and infection of dendritic cells and subsequent long-term transfer to T cells. *J Immunol* **2007**; 178:7840-8.
24. Purtscher M, Trkola A, Gruber G, et al. A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. *AIDS Res Hum Retroviruses* **1994**; 10:1651-8.
25. Casartelli N, Guivel-Benhassine F, Bouziat R, Brandler S, Schwartz O, Moris A. The antiviral factor APOBEC3G improves CTL recognition of cultured HIV-infected T cells. *J Exp Med* **2010**; 207:39-49.
26. Moris A, Nobile C, Buseyne F, Porrot F, Abastado JP, Schwartz O. DC-SIGN promotes exogenous MHC-I-restricted HIV-1 antigen presentation. *Blood* **2004**; 103:2648-54.
27. Garcia E, Pion M, Pelchen-Matthews A, et al. HIV-1 trafficking to the dendritic cell-T-cell infectious synapse uses a pathway of tetraspanin sorting to the immunological synapse. *Traffic* **2005**; 6:488-501.
28. Bouhlal H, Chomont N, Haeffner-Cavaillon N, Kazatchkine MD, Belec L, Hocini H. Opsonization of HIV-1 by semen complement enhances infection of human epithelial cells. *J Immunol* **2002**; 169:3301-6.
29. Banki Z, Kacani L, Rusert P, et al. Complement dependent trapping of infectious HIV in human lymphoid tissues. *AIDS* **2005**; 19:481-6.
30. Heyman B. The immune complex: possible ways of regulating the antibody response *Immunology Today* **1990**; 11:310-313.
31. Tanaka Y, Koido S, Ohana M, Liu C, Gong J. Induction of impaired antitumor immunity by fusion of MHC class II-deficient dendritic cells with tumor cells. *J Immunol* **2005**; 174:1274-80.
32. Turley SJ, Inaba K, Garrett WS, et al. Transport of peptide-MHC class II complexes in developing dendritic cells. *Science* **2000**; 288:522-7.

33. Lutz MB, Kukutsch N, Ogilvie AL, et al. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. *J Immunol Methods* **1999**; 223:77-92.
34. Rafiq K, Bergtold A, Clynes R. Immune complex-mediated antigen presentation induces tumor immunity. *J Clin Invest* **2002**; 110:71-9.
35. Regnault A, Lankar D, Lacabanne V, et al. Fcγ receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. *J Exp Med* **1999**; 189:371-80.
36. Carrington M, O'Brien SJ. The influence of HLA genotype on AIDS. *Annu Rev Med* **2003**; 54:535-51.
37. Goulder PJ, Watkins DI. Impact of MHC class I diversity on immune control of immunodeficiency virus replication. *Nat Rev Immunol* **2008**; 8:619-30.
38. Streeck H, Jolin JS, Qi Y, et al. Human immunodeficiency virus type 1-specific CD8+ T-cell responses during primary infection are major determinants of the viral set point and loss of CD4+ T cells. *J Virol* **2009**; 83:7641-8.
39. Andrieu JM, Lu W. A dendritic cell-based vaccine for treating HIV infection: background and preliminary results. *J Intern Med* **2007**; 261:123-31.
40. McElrath MJ, Haynes BF. Induction of immunity to human immunodeficiency virus type-1 by vaccination. *Immunity* **2010**; 33:542-54.
41. Picker LJ, Hansen SG, Lifson JD. New paradigms for HIV/AIDS vaccine development. *Annu Rev Med* **2012**; 63:95-111.
42. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. *Lancet* **2008**; 372:1881-93.
43. McElrath MJ, De Rosa SC, Moodie Z, et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. *Lancet* **2008**; 372:1894-905.
44. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. *J Infect Dis* **2005**; 191:654-65.
45. Pitisuttithum P, Gilbert P, Gurwith M, et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. *J Infect Dis* **2006**; 194:1661-71.
46. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. *N Engl J Med* **2009**; 361:2209-20.
47. McElrath MJ. Immune responses to HIV vaccines and potential impact on control of acute HIV-1 infection. *J Infect Dis* **2010**; 202 Suppl 2:S323-6.

## Figure Legends

**Figure 1 CD8<sup>+</sup> T cell proliferation induced by differentially loaded DC.** CD8<sup>+</sup> T cell expansion by DC loaded with HIV-C was 7-fold higher compared to HIV-Ig-DC ( $p \leq 0.05$ ) or HIV-DC ( $p \leq 0.05$ ). SEB-stimulated CD8<sup>+</sup> T cell proliferation served as positive control and was set 100, mDC and iDC as negative controls. The CD8<sup>+</sup> T cell-stimulatory capacity of DC loaded with HIV-CIg was intermediate. **63 words**

**Figure 2 Antiviral effects of *in vitro* generated HIV-specific CTLs.** HIV-C-DC-primed CTLs significantly ( $p \leq 0.001$ ) blocked the virus production in CD4<sup>+</sup>/CD8<sup>+</sup> T cell co-cultures compared to negative controls (w/o CD8<sup>+</sup> T cells, SEB), or HIV-Ig-DC-primed CTLs. Inhibition by HIV-CIg- and HIV-DC-primed CD8<sup>+</sup> T cells was intermediate. Percentages of infection compared to infected CD4<sup>+</sup> T cells are shown. **56 words**

**Figure 3 VCA of HIV-BaL opsonized with plasma from HIV-positive and healthy individuals.** The left panel shows IgG-coating of HIV opsonized with plasma from 35 HIV-positive (HIV<sup>+</sup> individuals) or 10 healthy controls, the right panel C3-deposition. The VCA using the above mentioned plasma samples was repeated three times using BaL (2x) or 92UG037 (1x). **52 words**

**Figure 4 Selection of HIV-C high or HIV-Ig high samples for Elispot analyses.** C3 fragments and HIV-specific Abs on the surface of HIV-BaL were analyzed by VCA following opsonization of the virus using plasma from HIV<sup>+</sup> individuals. Examples from 3 individuals

displaying either high C/low Ig (HIV-C high) or low C/high Ig (HIV-Ig high) are shown in this graph. **57 words**

**Figure 5 Elispot analyses using HIV-C high or HIV-Ig high virus preparations for DC exposure.** Induction of IFN $\gamma$  by HIV-C-high exposed DC was significantly stronger than that of HIV-Ig-high-DC ( $p \leq 0.0001$ ). As positive controls pepDC and HIV-C (human C serum, Quidel) were used, as negative controls iDC, HIV- and HIV-Ig-loaded DC (HIV, HIV-Ig (MRC IgG-pool)). **52 words**

**Figure 6A/B Intracellular localization of differentially opsonized HIV in DC.** HIV-C (green) co-localizes with HLA-ABC (red) in DC (A, left panel) to 94.6% (B), while HIV-Ig (green) only shows minor co-localization (31.5%) (B) with the MHC class I molecule (A, right panel). The HIV-CIg preparation showed intermediate co-localization (A, middle panel) (77.7%) (B). Cells were permeabilized and stained using labelled anti-human HLA-ABC mAb and anti-HIV p24<sup>Gag</sup>. **64 words**

**Fig. 7 Endosomal characterization of intracellular HIV localization in DC.** To illustrate, if the enhanced CTL-stimulatory capacity is due to enhanced degradation or multi-vesicular body co-localization, we stained HIV-, HIV-C- and HIV-Ig-incubated DCs with HIV-1-p24<sup>gag</sup> and CD63 or Lamp-1, respectively. No significant differences and only marginal co-localization with these markers were observable as depicted in this histogram plot. **56 words**



## **Supplementary Figure Legends**

**Supplementary Figure 1 DC-mediated CD8<sup>+</sup> T cell expansion measured by CFSE-labeling.** HIV-IgDC-mediated CD8<sup>+</sup> T cell proliferation compared to HIV-C-DC-CD8<sup>+</sup> T cells was detected by pre-staining T cells with 2.5 μM CFSE. Mean percentages of CFSE<sup>-</sup> [proliferated]/CD8<sup>+</sup> T cells of SEB-, HIV-, HIV-C- or HIV-Ig-DC-primed CD8<sup>+</sup> T cells from six experiments using 92UG037 and 92BR030 are shown. Data were analyzed by ANOVA and subsequently Bonferroni. **61 words**

**Supplementary Figure 2 VCA of HIV-BaL opsonized with plasma from HIV-positive individuals.** IgG- and C3-deposition on HIV opsonized with 35 plasma samples from HIV-positive individuals were analyzed by VCA. Differences in IgG- or C-amounts bound to the viral surface were analyzed by an unpaired Student's t test (2-tailed) and were shown to be non-significant. **51 words**

Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6A




Fig. 6B






Fig. 7



Suppl.Fig. 1



Suppl.Fig. 2

